266 related articles for article (PubMed ID: 23686326)
1. Choroidal naevi complicated by choroidal neovascular membrane and outer retinal tubulation.
Papastefanou VP; Nogueira V; Hay G; Andrews RM; Harris M; Cohen VM; Sagoo MS
Br J Ophthalmol; 2013 Aug; 97(8):1014-9. PubMed ID: 23686326
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma.
Papastefanou VP; Pefkianaki M; Al Harby L; Arora AK; Cohen VM; Andrews RM; Sagoo MS
Eye (Lond); 2016 Jun; 30(6):843-9. PubMed ID: 27034203
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for choroidal neovascularization associated with choroidal nevus.
Chiang A; Bianciotto C; Maguire JI; Park CH; Baker PS; Shields JA; Shields CL
Retina; 2012 Jan; 32(1):60-7. PubMed ID: 21886019
[TBL] [Abstract][Full Text] [Related]
4. Choroidal neovascularization associated with focal choroidal excavation.
Lee JH; Lee WK
Am J Ophthalmol; 2014 Mar; 157(3):710-8.e1. PubMed ID: 24345322
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
7. Management of Choroidal Neovascular Membranes Associated with Choroidal Nevi.
Munie MT; Demirci H
Ophthalmol Retina; 2018 Jan; 2(1):53-58. PubMed ID: 31047303
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma.
Khan MA; DeCroos FC; Storey PP; Shields JA; Garg SJ; Shields CL
Retina; 2014 Sep; 34(9):1750-6. PubMed ID: 24936941
[TBL] [Abstract][Full Text] [Related]
9. Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy.
Punjabi OS; Huang J; Rodriguez L; Lyon AT; Jampol LM; Mirza RG
Br J Ophthalmol; 2013 Aug; 97(8):1024-31. PubMed ID: 23759437
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography.
Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D
Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy.
Jyothi S; Chowdhury HR; Chong V; Sivaprasad S
Eye (Lond); 2010 Jun; 24(6):1018-23. PubMed ID: 19893588
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
17. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
20. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
